The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 22, 2026

Filed:

Sep. 20, 2022
Applicant:

Iolyx Therapeutics, Inc., Burlingame, CA (US);

Inventors:

Richard Graham, Irvine, CA (US);

Hovhannes J. Gukasyan, Orange, CA (US);

Elizabeth W. Jeffords, Hillsborough, CA (US);

Bhaskar Chaudhuri, San Jose, CA (US);

Assignee:

IOLYX THERAPEUTICS, INC., Burlingame, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/08 (2006.01); A61K 9/00 (2006.01); A61K 31/44 (2006.01); A61K 47/12 (2006.01); A61K 47/26 (2006.01); A61K 47/32 (2006.01); A61K 47/34 (2017.01); A61K 47/38 (2006.01);
U.S. Cl.
CPC ...
A61K 9/08 (2013.01); A61K 9/0048 (2013.01); A61K 31/44 (2013.01); A61K 47/12 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); A61K 47/34 (2013.01); A61K 47/38 (2013.01);
Abstract

The present invention relates to stable, ophthalmic pharmaceutical formulations of the phosphodiesterase-4 inhibitor, roflumilast, and methods of making the same. Novel ophthalmic pharmaceutical formulations of roflumilast can comprise a viscosity agent, a surfactant, and a buffer. In preferred embodiments, the pH of the ophthalmic pharmaceutical composition is between 6.0 and 6.7. Methods of making stable, ophthalmic pharmaceutical formulations of roflumilast can include separate active and inactive ingredient processes. Further, the methods can include clarity filtration to mitigate particle size aggregation and to create an optimized suspension. Further, the methods can include terminal sterilization of the final drug product.


Find Patent Forward Citations

Loading…